Dr Dana Rizk is Professor of Medicine in the Division of Nephrology at the University of Alabama at Birmingham (UAB) and a VOYXACT VISIONARY Study Investigator and Co-Chair of the Steering Committee.

Rare Pharmacy, the trusted leader and innovator in patient access and support services for personalized rare disease care, announced that it was selected by Otsuka as the exclusive specialty pharmacy ...

The novel drug atacicept was associated with significant reductions in proteinuria vs. placebo with comparable safety and no ...

Voyxact, an APRIL inhibitor, receives FDA accelerated approval for adults with primary IgA nephropathy to reduce proteinuria.

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The association between 24-hour collection and urine ...

Dear Dr. Roach: My husband had many tests for bacteria in his urine. Three months ago, he had no protein in the urine; two months ago, the number of protein was 20; one month ago, the number was 100.

Use of a mathematical model of serum-free light chain decline to identify a kinetic predictive marker of survival in patients with newly diagnosed multiple myeloma treated with bortezomib plus ...

A investigator reported that sibeprenlimab halved baseline proteinuria levels over 12 months in trial patients with IgA nephropathy. Sibeprenlimab continues to reduce proteinuria in patients with IgA ...

Sudden cardiac arrest, while rare, was somewhat more likely for young adults whose lab values indicated proteinuria approximately 10 years prior. The findings were based on a study of 6.8 million ...